News & Investors

Want to stay updated? Subscribe to our newsletters. For free.

Have questions? Our live support would be happy to help you.

Year: 2017

Epigenomics AG issues new shares by way of private placement

PDF Publication of Inside Information according to Article 17 MAR Not for distribution in the United States of America Berlin, Germany, September 20, 2017 – Epigenomics AG, Berlin, Germany (Frankfurt Prime Standard: ECX, ISIN: DE0000A11QW50), announces that the Company is raising approximately EUR 5.5 million of gross proceeds in a share capital increase by way of private […]

Read more

Epigenomics AG issues convertible bonds

PDF Berlin (Germany) and Germantown, MD (U.S.A.), September 8, 2017 – Epigenomics AG (FSE: ECX, OTCQX: EPGNY), or the “Company”, today announced that it has issued convertible bonds with a nominal value of EUR 7.1 million to Cathay Fortune International Company Limited (CFIC) excluding pre-emptive rights of existing shareholders. The issuance of the convertible bonds, […]

Read more

Epigenomics Commences Post Approval Study on Epi proColon®

PDF Berlin (Germany) and Germantown, MD (U.S.A.), August 30, 2017 – Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY), today announced the initiation of a Post Approval Study (PAS), Performance of Epi proColon in Repeated Testing in the Intended Use Population (PERT) – NCT03218423. The PERT trial is being conducted in concert with the US […]

Read more

Epigenomics AG Announces 2017 Second Quarter and Six Months Financial Results

PDF -Reimbursement in the United States is a focus of the company as it will have the greatest impact upon commercial adoption of Epi proColon -The expected issuance of the convertible bond as agreed in the voluntary takeover offer will improve the financial position of the company with the addition of approximately EUR 6.5 million […]

Read more

Epigenomics AG: Notice of Loss pursuant to § 92 par. 1 AktG

PDF Publication of Inside Information according to Article 17 MAR August 7, 2017 – The Executive Board of Epigenomics AG (FSE: ECX; OTCQX: EPGNY) notifies that according to its best judgment a cumulative loss of more than half of the nominal share capital of the company has been incurred. This is mainly attributable to budgeted losses […]

Read more

Epigenomics AG: Voluntary public takeover offer by Summit Hero Holding not successful

PDF Berlin, July 12, 2017 – Summit Hero Holding GmbH (“bidder”) announced today that, as of expiry of the extended acceptance period at midnight (24:00 CEST) on July 7, 2017, 62.13 percent of Epigenomics outstanding shares have been tendered under the voluntary public takeover offer or were held by or attributed to the bidder. Consequently, […]

Read more